Biogen Inc. has finalized a $5.6 billion acquisition of Apellis Pharmaceuticals, paying $41 per share, which reflects an 86% premium to Apellis' recent stock price. The announcement triggered a remarkable 135% surge in Apellis shares as investors react to the deal's significance in enhancing Biogen's portfolio in immunology and rare diseases. This strategic acquisition positions Biogen to potentially add $1.54 billion in sales by 2030, significantly bolstering its market presence.
Loading timeline…
